@entity2 is the leading cause of @entity204 worldwide, and @entity3 always results in a poor prognosis. However, therapeutic progress is hampered by a deficiency of appropriate pre-clinical metastatic models. To bridge this experimental gap, we developed an in  vivo metastatic model via subcutaneous (s.c.) injection. The original cell line (XL-2) adopted in this model was newly isolated from the ascites of a @entity1 with extensive @entity2220 , thereby avoiding any alteration of its initial molecular biology features from artificial serial cultivation. After comprehensive phenotypical and histological analysis, it was identified as a @entity2220 cell line. Additionally, the drug test showed that XL-2 cell line was sensitive to @entity1205 , and resistant to @entity632 , indicating it might serve as a cell line model of drug resistance for identifying mechanisms of @entity5 resistant to @entity632 . Through this s.c. model, we further obtained a highly metastatic cell line (designated XL-2sci). The metastatic rate of @entity19 in XL-2 group was 3/10, in contrast to the rate of 9/10 in XL-2sci group. Optical imaging, micro-computed tomography (micro-CT) scanning and Transwell assays were further applied to identify the enhanced metastatic capacity of Xl-2sci cells both in  vivo and in  vitro. Compared with XL-2 cells, ITRAQ labeled proteomics profiling study showed that some @entity5 @entity3 -associated proteins were upregulated in XL-2sci cells, which also indicated the reliability of our model. Proliferation ability of XL-2 and XL-2sci were also evaluated. Results showed that highly metastatic XL-2sci possessed a decreased proliferation capacity versus XL-2, which demonstrated that its increased metastatic activity was not facilitated by a faster growth rate. In conclusion, we successfully developed an in  vivo metastatic model using a newly established @entity2220 cell line, which will be beneficial to further investigations of @entity2 @entity3 and to the development of anti- @entity3 drugs.

Establishment of a highly metastatic model with a newly isolated XXXX cell line.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung cancer', 'lung cancer'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity204 :: ('MESH:D003643', 'Disease') :: ['malignancy-related death'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['metastases of lung adenocarcinoma', 'lung adenocarcinoma']
@entity2220 :: (MESH:C538231,Disease) :: ['lung adenocarcinoma']
